![]() |
|
|
Vol. 303, Issue 2, 704-710, November 2002
Department of Cell Biology and Neuroscience, Rutgers University,
Piscataway, New Jersey
To characterize the effects of morphine on serotonin (5-HT) in the
central nervous system, we used microdialysis in freely behaving
rats. Subcutaneous injection of morphine sulfate produced a
dose-dependent increase in extracellular 5-HT in the dorsal raphe
nucleus (DRN) and a forebrain site, the nucleus accumbens (NAcc). To
determine the site of action for this effect, the opioid receptor
antagonist naltrexone was infused into either the DRN or NAcc.
Naltrexone infusion (300 µM) into the DRN but not the NAcc attenuated
the increase in 5-HT elicited by systemic morphine (20 mg/kg). This
suggests that morphine acts in the DRN to alter the activity of 5-HT
neurons that project to NAcc. Consistent with this conclusion, infusion
of the GABAA receptor antagonist bicuculline (100 µM)
into the DRN but not the NAcc also blocked the effect of systemic
morphine. Similarly, the effect of systemic morphine was blocked by
infusion into the DRN of the GABAA receptor agonist
muscimol (30 µM) and attenuated by the GABAB receptor agonist (±)-baclofen (100 µM). This provides evidence that morphine indirectly influences 5-HT release via opioid receptors on GABAergic neurons in the DRN. A new finding is that ionotropic glutamate receptor
antagonists [kynurenate or a mixture of
(±)-2-amino-5-phosphonopentanoic acid and
6,7-dinitro-quinoxaline-2,3-dione] infused in the DRN also attenuated
the effect of systemic morphine. These results suggest that morphine
acts on GABAergic and glutamatergic afferents to indirectly influence
the activity of 5-HT neurons in the DRN. Understanding the details of
this neural circuitry may provide new leads for treatment of opiate addiction.